Citations

Clear

3942 citation(s) found for "To, Van".

Impact of type of reduced‐intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma
Ahn, Kwang Woo , Khanal, Manoj , Litovich, Carlos, Chhabra, Saurabh , Cairo, Mitchell S. , Mei, Matthew , William, Basem M. , Nathan, Sunita , Bejanyan, Nelli , Olsson, Richard F. , Poel, Marjolein van der , Steinberg, Amir , Kanakry, Jennifer A. , Černý, Jan , Farooq, Umar , Seo, Sachiko , Kharfan‐Dabaja, Mohamed A. , Sureda, Anna , Fenske, Timothy S. , Chhabra, Saurabh , Cairo, Mitchell , William, Basem , Farooq, Umar , Kharfan-Dabaja, Mohamed A , Sureda, Anna , Hamadani, Mehdi , Olsson, Richard F , Mei, Matthew , Ahmed, Sairah , Ghosh, Nilanjan , Mussetti, Alberto , Dahi, Parastoo B , Hamadani, Mehdi

Mayo Clinic

British Journal of Haematology | April 21, 2020 | Volume: 190 | Issue: 4 | Pages: 573-582

10.1111/bjh.16664 | PMID 32314807 Get It

SummaryReduced‐intensity conditioning (RIC) allogeneic haematopoietic cell transplantation (allo‐HCT) is a curative option for select relapsed/refractory Hodgkin lymphoma (HL) patients; however, there are sparse data to support superiority of any particular conditioning regimen. We analyzed 492 adult patients undergoing human leucocyte antigen (HLA)‐matched sibling or unrelated donor allo‐HCT for HL between 2008 and 2016, utilizing RIC with either fludarabine/busulfan (Flu/Bu), fludarabine/melphalan (Flu/Mel140) or fludarabine/cyclophosphamide (Flu/Cy). Multivariable regression analysis was performed using a significance level of <0·01. There were no significant differences between regimens in risk for non‐relapse mortality (NRM) (P = 0·54), relapse/progression (P = 0·02) or progression‐free survival (PFS) (P = 0·14). Flu/Cy conditioning was associated with decreased risk of mortality in the first 11 months after allo‐HCT (HR = 0·28; 95% CI = 0·10–0·73; P = 0·009), but beyond 11 months post allo‐HCT it was associated with a significantly higher risk of mortality, (HR = 2·46; 95% CI = 0·1.32–4·61; P = 0·005). Four‐year adjusted overall survival (OS) was similar across regimens at 62% for Flu/Bu, 59% for Flu/Mel140 and 55% for Flu/Cy (P = 0·64), respectively. These data confirm the choice of RIC for allo‐HCT in HL does not influence risk of relapse, NRM or PFS. Although no OS benefit was seen between Flu/Bu and Flu/Mel 140; Flu/Cy was associated with a significantly higher risk of mortality beyond 11 months from allo‐HCT (possibly due to late NRM events).
Anesthesia for TORS for Oropharyngeal Carcinoma: Factors Associated with Prolonged Phase I Postanesthesia Recovery
Puccinelli, Cassandra L., Moore, Eric J. , Yin, Linda X. , Janus, Jeffrey R. , Abel, Kathryn M. Van , Van Abel, Kathryn M , Yin, Linda X , Price, Daniel L. , Weingarten, Toby N.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | April 21, 2020 | Volume: 163 | Issue: 3 | Pages: 531-537

10.1177/0194599820915529 | PMID 32312161 Get It

ObjectivesClinical variables affecting anesthetic recovery following transoral robotic surgery (TORS) to resect oropharyngeal squamous cell carcinoma have not been described. We aimed to explore risk factors associated with prolonged postanesthesia recovery following TORS.Study DesignRetrospective case‐control study.SettingTertiary referral center, January 2010 to November 2016.Subjects and MethodsPatients included adults undergoing primary TORS ± neck dissection for oropharyngeal squamous cell carcinoma. Patients were categorized by phase I recovery time into the “goal” recovery group (75th percentile [lower 3 quartiles], n = 272) and the “prolonged” recovery group (n = 91). Univariate and multivariate logistic regression analyses were performed to assess the associations between clinical characteristics and prolonged phase I recovery.ResultsA total of 363 patients were included. Median (interquartile range) duration of postanesthesia recovery was 1.5 hours (1.0‐2.0). Prolonged recovery was associated with isoflurane (odds ratio, 2.83 [95% CI, 1.56‐5.14], P <. 001), midazolam (2.77 [1.50‐5.12], P =. 001), and larger opioid doses (1.26 [1.01‐1.58] per 10‐mg intravenous morphine equivalents, P =. 040) and inversely associated with multimodal antiemetic therapy (0.34 [0.15‐0.78], P =. 011). Prolonged cases had higher rates of postoperative nausea and vomiting (n = 43 [47.2%] vs 86 [31.6%], P =. 008), respiratory depression (28 [30.8%] vs 12 [4.4%], P <. 001), sedation (Richmond Agitation‐Sedation Scale < –2; 26 [28.6%] vs 35 [12.9%], P =. 001), severe pain (numeric rating score ≥7; 31 [34.4%] vs 45 [17.2%], P =. 001), and longer hospital stays (4 vs 3 days, P <. 001).ConclusionsSeveral anesthetic factors are associated with anesthesia recovery duration, which may be shortened by efforts to reduce postoperative sedation, severe pain, and nausea/vomiting. Shortened anesthesia recovery time may reduce hospital stay.
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Wen, Patrick Y. , Weller, Michael , Lee, Eudocia Q. , Barnholtz‐Sloan, Jill S. , Barthel, Floris P , Batchelor, Tracy T. , Chang, Susan M. , DeGroot, John, Hegi, Monika E. , Huang, Raymond Y. , Lassman, Andrew B. , Lim, Michael , Mellinghoff, Ingo K. , Minniti, Giuseppe , Nathanson, David A. , Platten, Michael , Preusser, Matthias , Roth, Patrick , Sanson, Marc , Schiff, David , Short, Susan , Taphoorn, Martin , Tonn, Joerg-Christian, Tsang, Jonathan , Verhaak, Roel G.W. , Deimling, Andreas von , Zadeh, Gelareh , Reardon, David A. , Aldape, Kenneth , Bent, Martin J. van den , Weller, Michael , Short, Susan C , van den Bent, Martin J , Barnholtz-Sloan, Jill S , Platten, Michael , Preusser, Matthias , Sanson, Marc , von Deimling, Andreas , Mellinghoff, Ingo K , Huang, Raymond , Roth, Patrick , Barthel, Floris P , Wen, Patrick Yung , Alexander, Brian M. , Bindra, Ranjit S. , Chiocca, E Antonio , Cloughesy, Timothy F. , Galanis, Evanthia , Gilbert, Mark R. , Horbinski, Craig , Rhun, Émilie Le , Mehta, Minesh P. , Tonn, Joerg-Christian , Wick, Wolfgang

Mayo Clinic

Neuro-Oncology | April 20, 2020 | Volume: 22 | Issue: 8 | Pages: 1073-1113

10.1093/neuonc/noaa106 | PMID 32328653 Get It

Abstract Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. In addition, novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies, and viral therapies will be reviewed, as well as the current challenges and future directions for research.
cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading
Louis, David N. , Wesseling, Pieter , Aldape, Kenneth , Capper, David , Cree, Ian A. , Figarella‐Branger, Dominique , Fouladi, Maryam, Haberler, Christine , Hawkins, Cynthia , Komori, Takashi, Ng, Ho‐Keung , Orr, Brent A. , Paulus, Werner, Pietsch, Torsten , Reifenberger, Guido , Rosenblum, Marc, Rous, Brian , Sahm, Felix , Sarkar, Chitra , Solomon, David A. , Tabori, Uri , Bent, Martin J. van den , Deimling, Andreas von , Weller, Michael , White, Valerie A. , Ellison, David W. , Figarella-Branger, Dominique , Pietsch, Torsten , Sarkar, Chitra , Solomon, David A , Weller, Michael , van den Bent, Martin J , Orr, Brent A , Wesseling, Pieter , von Deimling, Andreas , Tabori, Uri , Sahm, Felix , Capper, David , Brat, Daniel J. , Eberhart, Charles G. , Fouladi, Maryam , Fuller, Gregory N. , Giannini, Caterina , Kros, Johan M. , Park, Sung-Hye , Perry, Arie , Rosenblum, Marc

Mayo Clinic

Brain Pathology | April 20, 2020 | Volume: 30 | Issue: 4 | Pages: 844-856

10.1111/bpa.12832 | PMID 32307792 Get It

Abstract cIMPACT‐NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) was established to evaluate and make practical recommendations on recent advances in the field of CNS tumor classification, particularly in light of the rapid progress in molecular insights into these neoplasms. For Round 2 of its deliberations, cIMPACT‐NOW Working Committee 3 was reconstituted and convened in Utrecht, The Netherlands, for a meeting designed to review putative new CNS tumor types in advance of any future World Health Organization meeting on CNS tumor classification. In preparatory activities for the meeting and at the actual meeting, a list of possible entities was assembled and each type and subtype debated. Working Committee 3 recommended that a substantial number of newly recognized types and subtypes should be considered for inclusion in future CNS tumor classifications. In addition, the group endorsed a number of principles—relating to classification categories, approaches to classification, nomenclature, and grading—that the group hopes will also inform the future classification of CNS neoplasms.
The “Trans-Amplicon” in Myeloma; a Mechanism of Clonal Selection Favoring Retention of Derivative Chromosomes Involved in Translocations.
Masri, Azzah Al, Tschumper, Renee C. , Wier, Scott Van, Price-Troska, Tammy, Jelinek, Diane F., Price-Troska, Tammy, Fonseca, Rafaël

Mayo Clinic

Blood | April 19, 2020 | Volume: 106 | Issue: 11 | Pages: 4346-4346

10.1182/blood.v106.11.4346.4346 Get It

Abstract Background: Multiple mechanisms exist for the positive selection of genes involved in oncogenesis such as gene amplification and transcriptional deregulation associated with chromosome translocations. Here we describe the case of a myeloma cell line that over time acquired extra copies of a derivative chromosome 4 involved in the t(4;14). These changes occurred over time both in vitro (in the generated JMW myeloma cell lines) as well as in vivo from extramedullary myeloma samples collected from the patient at various time points. In the case of the t(4;14)(p16;q32) 30% can be unbalanced translocations, always with loss of the der(14) and consequent loss of the FGFR3 gene expression, suggesting an indispensable role for MMSET located in the der(4). Results: We performed serial analysis on patient samples obtained at 9, 10 and 12 mos from diagnosis, along with a time course analysis of the cell line. At diagnosis the patient tumor cells displayed a complex clinical karyotype subsequently characterized by hypodiploidy, a t(4;14)(p16;q32), 13 monosomy and 17p13.1-. The remaining chromosome 13 and 17 were involved in an unbalanced reciprocal translocation. Notably, over time the cell line duplicated the total chromosome number becoming near-tetraploid. At the time of diagnosis, FISH analysis was performed on the patient sample revealing the translocation t(4;14)(p16.3:q32) in nearly all cells. The t(4;14) was also present in the stable cell line. It was noted that the patient cells exhibited more than one fusion signal per cell for the t(4;14) by FISH. As the disease progresses both in vitro and in vivo, the number of t(4;14)(p16.3:q32) fusion signals detected per cell increased with time suggesting a positive selection of the derivative chromosomes of the translocation. We further analyzed the t(4;14) in the JMW cells by FISH using MMSET/VH, and FGFR3/CH probe combinations. The full-length (MMSET/FGFR3+VH/CH) probe was used to detect the total number of fusions in the JMW cells. At the time of analysis (cell line passage #23), the majority of the cells (69%) had 6 fusion signals per cell while 23% had 5 fusions and 8% of the cells had 4 fusions. We found that most of the cells (88%) displayed 4 fusion signals detected using the MMSET/VH probes. In parallel studies using the FGFR3/CH probes, 61% of the cells had 2 fusion signals and 39% with 1 fusion signal. It is evident that the tumor cells display positive selection of the derivative chromosome der(4) of the t(4;14)(p16.3;q32), accompanied by an increased dosage of the target gene (MMSET) upregulated by the translocation. Conclusion: We present evidence for the amplification of the translocated chromosome in multiple myeloma, which we have termed “trans-amplicons”. Trans-amplicons may provide a selective growth and survival advantage to the myeloma tumor cells in an analogous manner to amplicons of DNA segments, but with much more powerful transcriptional consequences. Importantly, the evolution of genomic instability exemplified by the “trans-amplicons” in the patient cells was paralleled in vitro in the JMW cells.
Submicroscopic Interstitial Deletions in 13q14 Are Detectable in Metaphase Cells by Fluorescence In Situ Hybridization (FISH) with D13S319 in Chronic Lymphocytic Leukemia (B-CLL).
Dyke, Daniel L. Van , Stockero, Kimberly J., Fink, Stephanie, Smoley, Stephanie A., Paternoster, Sarah F., Schwager, Susan M., Call, Timothy G. , Dewald, Gordon W., Shanafelt, Tait D. , Zent, Clive S. , Kay, Neil E.

Mayo Clinic

Blood | April 19, 2020 | Volume: 106 | Issue: 11 | Pages: 3278-3278

10.1182/blood.v106.11.3278.3278 Get It

Abstract Background: Results of conventional cytogenetic studies on specimens processed without B-cell mitogens are usually normal in B-CLL: this observation is often attributed to lack of mitotic B-CLL cells. Using metaphase FISH with D13S319, we now have evidence that these apparently normal mitotic B-CLL cells often exhibit submicroscopic interstitial deletions in 13q14. This observation indicates B-CLL cells do divide in unstimulated cultures, but the abnormal metaphases are not detected because the abnormalities are submicroscopic and represent a low percentage of proliferating cells. Methods: We studied 12 patients with B-CLL who had normal metaphases by conventional cytogenetics, but abnormal interphase nuclei by FISH with D13S319. This cohort consisted of 7 females and 5 males who ranged in age from 50 to 87 years. Clinical information was available for 11 patients: Rai stages were 0, I, II, III, or IV for 6, 1, 1, 2, and 1 patients, respectively; 8 patients received treatment and 3 have died. Conventional cytogenetic studies and metaphase FISH were done on bone marrow specimens that were processed by standard 24 and 48-hour unstimulated cultures with Chang Medium BMC. Interphase FISH studies were done on blood or bone marrow (collected within 3 days of specimens for conventional cytogenetic studies) using probes to detect anomalies of chromosomes 6, 11, 12, 13, 14 and 17. For each patient, metaphase FISH was done with commercial probes from Vysis Inc., Downers Grove, IL for D13S319/13q34 using leftover fixed cells from conventional cytogenetics studies. Results: Metaphase FISH results were normal for 3 bone marrow specimens: the remaining 9 specimens had 1.9 to 13.8% metaphases with interstitial deletions of 13q14. One patient had a cytogenetically visible chromosome 13 deletion in 2.2% of metaphases. In the remaining 8 specimens, the size of the abnormal 13 was similar to the normal 13 homolog and other acrocentric chromosomes. By comparison, interphase FISH revealed 13 to 93% nuclei with 13q-x1 or 13q-x2. Seven patients had additonal anomalies in their interphase nuclei; 3 had 11q-, 2 had 17p-, 1 had +12 and 1 had +IGH. Conclusions: This investigation indicates that metaphase FISH detects submicroscopic deletions in chromosome 13 as well as infrequent mitotic B-CLL cells in patients who have normal conventional cytogenetic results. Therefore, metaphase FISH is a novel and useful technique to detect abnormal mitotic cells in B-CLL in cultures without special B-cell mitogens. The prognostic significance of abnormal metaphase FISH results is still under investigation. We speculate that this method will allow for identification of more aggressive proliferating disease even in so-called “favorable” prognostic groups based on interphase FISH results.
SNP Genotypes Show Association with Common Toxicities during both VAD Induction and High Dose Melphalan with Autologous Transplant Support in Intergroup Trial S9321 for Myeloma: From the Bank on a Cure.
Ness, Brian G. Van , Crowley, John C., Ramos, Christine, Grindle, Suzanne, Rasmussen, Erik, Hoering, Antje , Greipp, Philip R., Barlogie, Bart , Durie, Brian G.M.

Mayo Clinic

Blood | April 19, 2020 | Volume: 106 | Issue: 11 | Pages: 3488-3488

10.1182/blood.v106.11.3488.3488 Get It

Abstract Patients with multiple myeloma show significant heterogeneity with respect to progression, therapeutic response and toxicities. Part of the Bank On A Cure project is to examine potential genetic polymorphisms that may be associated with common toxicities monitored in clinical trials. The SWOG/ECOG intergroup trial S9321 therapy includes VAD induction followed by randomization to high dose melphalan with autologous transplant support. Paticularly important toxicities with VAD include infection, thrombosis and hyperglycemia; and with melphalan toxicities in GI function are noted. Toxicities and genotypes were assessable during VAD induction on 569 patients; and during high dose melphalan on 161 patients. Toxicities examined included an array of symptoms: cardiovascular, flu-like, GI, neurologic, infection, lung, metabolic, and pain. Grade 3 toxicities found in at least 20 patients were compared to SNP genotypes. For VAD induced toxicities,TNF-alpha SNP genotypes showed association with fatigue, dyspnea and thrombosis; CYP3A4 SNP genotypes showed association with fatigue; DNA repair SNP genotypes in XRCC1 showed associations with infection, hyperglycemia and dyspnea; LT-alpha SNP genotypes showed association with dyspnea; and IL-6 and IL-10 SNP genotypes were marginally associated with neuropathy. After high dose melphalan, diarrhea was associated with SNP genotypes in TGF-beta, CYP3A4 and ERCC2. Interestingly, IL-6 polymorphisms were significantly associated with infection. The p values on the above associations ranged from .05 to .004. In addition, we noted ethnic distributions of some SNP genotypes were significantly different; and significant ethnic disparities in therapy induced hyperglycemia, fatigue, dyspnea and thrombosis were noted (p values range from .04 to .009). Of particular note is that the high producer IL-6 genotype is present in over 90% African Americans, compared to 35% Caucasians. Details of each association will be presented. Not all associations can easily be explained by known biologic function of the genotype, and it is important to qualify these results, as the likelihood of seeing some genotype associations by chance is quite high given the number of comparisons made. Further, we are continuing to examine additional prognostic factors that may, together with genotypes, provide collective predictors of toxicities. We consider these associations as targets for further study through the increasing sample acquisition in the Bank On A Cure project.
Clinical Significance of the Tumor Suppressor p53 Codon 72 Polymorphic Variants in Multiple Myeloma.
González-Paz, Natalia, Kumar, Shaji , Price-Troska, Tammy, Wier, Scott Van, Ahmann, Gregory , Henderson, Kimberly J., Kyle, Robert A. , Greipp, Philip R., Chng, Wee Joo , Price-Troska, Tammy, Gertz, Morie A. , Fonseca, Rafaël

Mayo Clinic

Blood | April 19, 2020 | Volume: 106 | Issue: 11 | Pages: 5102-5102

10.1182/blood.v106.11.5102.5102 Get It

Abstract Background: The p53 tumor suppressor gene has a common sequence polymorphism that results in either proline or arginine at amino-acid position 72. The Pro72 and Arg72 variants have been reported to differ in its functional activity. The Arg72 variant induces apoptosis more efficiently than Pro72 variant by its greater ability to localize to the mitochondria and increase the release of cytochrome c into the cytoplasm. In addition, recent studies have demonstrated that Arg72 variant was a better suppressor of cellular transformation, an activity believed to rely on the pro-apoptotic function of p53. Moreover, the Pro72 variant has been associated with a higher incidence of tumors. Aim: To evaluate the effect of the polymorphic variants of codon 72 and clinical outcome in patients with plasma cell malignancies. Patients and Methods: We analyzed 79 patients with plasma cell malignancies seen at Mayo Clinic between 2000 and 2003. Genomic DNA was extracted from CD138+ sorted plasma cell from bone marrow aspirates. PCR amplification of codon 72 and posterior sequencing was used for the analysis. Results: A total of 79 patients were analyzed. Thirty-four patients (34%) were heterozygous for p53, 57 (59%) homozygous for Arginine and 6 (6%) homozygous for Proline. The distribution among disorders was as follow, 52 patients had MM, 14 patients with SMM and 13 with MGUS. Among patient with MM 25% were Pro/Arg heterozygous, 71 % were Arg/Arg homozygous and 3.8% Pro/Pro homozygous. Survival data among MM patients and genotype were analyzed to Kaplan- Meier method. No significant differences were found among patients who carried homozygous (72R) or heterozygous genotype and overall survival. We exclude the analysis in MGUS and SMM for a low number of patients available. Conclusions: These findings indicate that codon 72 arginine p53 may not be associated with a prolonged survival in patients with Multiple Myeloma, but further study is needed to assess whether this polymorphism is associated with progression of MGUS to MM, age of onset, clinical manifestations, response to treatment etc.
Plasma Cells from Secondary Plasma Cell Leukemia Display Different Cytogenetics Pattern When Compared with Primary Plasma Cell Leukemia.
González-Paz, Natalia, Wier, Scott Van, Santana-Dávila, Rafael , Ahmann, Gregory , Price-Troska, Tammy, Henderson, Kimberly J., Kyle, Robert A. , Greipp, Philip R., Gertz, Morie A. , Fonseca, Rafaël

Mayo Clinic

Blood | April 19, 2020 | Volume: 106 | Issue: 11 | Pages: 3267-3267

10.1182/blood.v106.11.3267.3267 Get It

Abstract Background: Plasma cell leukemia (PCL) is a rare plasma cell (PC) dyscrasia which may be designated as primary (PPCL) or de novo PCL when recognized at the time of diagnosis and secondary (SPCL) when there is leukemic transformation of a previously recognized multiple myeloma (MM). PCL has been reported to exhibit distinct clinical and immunophenotypic features that distinguish it from MM, but little is known about the specific genetics of this disease. To better understand the genetic features of the clonal PC from PPCL and SCPL we assessed in these patients the molecular and cytogenetic abnormalities most commonly found in MM. Patients and Methods: In our study we analyzed 3 groups of patients; 18 with PPCL, 23 with SPCL and a control group of 345 newly diagnosed MM previously published. Diagnostic criteria for PCL followed the presence of &gt;2 x103/L PC in PB (Kyle et al. Arch Intern Med1974; 133–813–8). Cytogenetic abnormalities were assessed by the c-Ig FISH method; mutational analysis was performed using Conformational-sensitive gel electrophoresis (CSGE). Methylation was analyzed by methyl specific PCR (MSP) after bisulfite genomic DNA modification. Results: Translocation of immunoglobulin heavy chain with Cyclin D1 (t (11; 14)) was present in 76.9% (10 of 13) of PPCL, 71% (5 of 7) of SPCL, in contrast to 15.8% (53 of 336) of MM cases. Translocations’ involving the FGFR3-MMSET genes (4p16.3 locus) and c-MAF (16q32) genes were not observed among 10 patients studied with PPCL, but were present in 12.7 % each in SPCL. The t (4;14)(p16;q32) was present in 12.7% cases of MM and the t(14;16)(q32;q23) was present in 4.6 % of MM cases. Deletion of 17p13.1 (p53 locus) was found in 10% (37 of 345) of MM cases, 53.8% (7 of 13) for PPCL and 42.8% (3 of 7) for SPCL. Deletion of 13q was present in 54.2% (176 of 325) of MM, 76.9 % (10 of 13) of PPCL and 57.1% of SPCL. Ras mutations were found in 15% (2/13) of PPCL, located in codon 1 and 2 of the K-ras gene. In addition, 23% for SPCL presented mutations in the N-ras gene. Two mutations were located in codon 2 of N-ras and 1 patients in showed a mutation in codon 1 of K-ras gene. Ras mutations were present in 27% of MM cases. Mutations for p53 gene were present in 30.7% (4/13) of PPCL, 17% (3/17) for SPCL and 5% for MM. Methylation specific PCR for p16 gene was found in 23% (3/13) of PPCL, 29% of SPCL and 33.9% (149/439) of MM. Hypermethylation of p14 was not detected in PPCL but a 23 % was found in SPCL. Conclusions: In this study we demonstrate that PCs from PPCL more frequently carry the t (11; 14). Comparing SPCL and MM, PC’s from de novo PPCL do not show t (4; 14) or (16; 14). Deletion of 13q was more prevalent among patients with PPCL. Ras mutations appear to be as frequent in MM as in PPCL and SPCL. Mutations in p53 appeared to be more prevalent in PPCL than in SPCL and MM. Hypermethylation of p16 does not differ while hypermethylation of p14 is more frequent in SPCL than PPCL. These characteristics may lead to a different onset or disease evolution of PPCL compared to MM and secondary plasma cell leukemia and this may be important for diagnostic and treatment.
SNP Genotypes as Prognostic Factors Associated with Staging in Myeloma: The First Combined SNP Association Analysis of SWOG, ECOG, and MRC Clinical Trials from the Bank on a Cure.
Ness, Brian Van, Crowley, John, Blood, Emily, Rasmussen, Erik, Ramos, Christine, Grindle, Suzanne, Hoering, Antje , Greipp, Philip R., Barlogie, Bart , Durie, Brian G.M. , Morgan, Gareth J. , Johnson, David C.

Mayo Clinic

Blood | April 19, 2020 | Volume: 106 | Issue: 11 | Pages: 3489-3489

10.1182/blood.v106.11.3489.3489 Get It

Abstract Although multiple myeloma is clinically defined as the accumulation of clonal, malignant plasma cells in the bone marrow, the disease shows significant heterogeneity with regard to progression and therapeutic response. It is likely that germline genetic polymorphisms contribute significantly to an individual’s disease course and response. Bank On A CureTM (BOAC) is a collaborative project initiated with the International Myeloma Foundation (IMF) to develop a DNA bank of myeloma patient samples, through international cooperation. As the bank continues to expand, it provides a resource for the development of cooperative partnerships to assess specific clinical trials as well as conglomerate data. In this study, we have combined data from 3 phase III trials: ECOG trial E9486 (VBMCP + cyclophosphamide or interferon); SWOG trial 9321 (VAD induction followed by randomization to PBSC-supported high dose therapy versus standard dose therapy of VBMCP); and the MRC7 trial (comparing conventional chemotherapy [ABCM] with intravenous chemotherapy and high dose melphalan [CVAMP + HDM +PBSCT]). Five single nucleotide polymorphisms were examined based on associations demonstrated in previous individual trials: GSTP1, IL-6, LT-a, TNF-a, and ERCC2 (DNA repair). Patient samples included 412 from E9486, 569 from S9321, and 232 from MRC7 (total=1213). As a combined data set, genotype associations with overall survival did not reach statistical significance, suggesting SNP associations with survival may be therapy specific. One single association that did reach significance in the conglomerate data was TNF-a genotype association with age of disease onset (the high producer variant AA genotype showing a 5 year later age of onset than the AG/GG genotypes, or the overall mean of the trial, age 61 vs 56; p=.03). This is interesting in light of reports suggesting high production of TNF-a is found in myeloma patients and may actually promote myeloma. Yet, high production may also delay disease onset due to its role in other immunologic processes. Additional parameters including genotype associations with bone disease, CR rates, toxicities, and stage are being evaluated and will be presented. Preliminary results show that when SNPs from S9321 were included in a linear regression model, genotype risk groups could be identified; showing 73% correct association with ISS stage 1, and 75% correct association with ISS stage 3. This model, however, was not validated in the E9486 trial, with less than 50% genotype predictive ISS stage association. A number of highly significant ethnic genotype associations were noted, and are presented in a separate abstract. Given the likely complex interactions of multiple genetic variations, collective genotype comparisons may be required from larger pooled data sets BOAC is assembling to increase significant associations.